Fertility and Sterility
Volume 91, Issue 3 , Pages 929.e13-929.e15 , March 2009

A case of a methotrexate-resistant ectopic pregnancy in which dactinomycin was effective as a second-line chemotherapy

Received 2 July 2008 ,Revised 30 September 2008 ,Accepted 3 October 2008.

References 

  1. Winter AE, Bergman WD, Fields C. Combined intra- and extrauterine pregnancy. Am J Obstet Gynecol. 1957;74:170–177
  2. Orvieto R, Kruchkovich J, Zohav E, Rabinson J, Anteby EY, Meltcer S. Does methotrexate treatment for ectopic pregnancy influence the patient's performance during a subsequent in vitro fertilization/embryo transfer cycle?. Fertil Steril. 2007;88:1685–1686
  3. Yao M, Tulandi T. Current status of surgical and non-surgical treatment of ectopic pregnancy. Fertil Steril. 1997;67:421
  4. Bixby S, Tello R, Kuligowska E. Presence of yolk sac on transvaginal sonography is the most reliable predictor of single dose methotrexate treatment failure in ectopic pregnancy. J Ultrasound Med. 2005;24:591
  5. Lipscomb GH, Stovall TG, Ling FW. Nonsurgical treatment of ectopic pregnancy. N Engl J Med. 2000;343:1325–1329
  6. Potter MB, Lepine LA, Jamieson DJ. Predictors of success with methotrexate treatment of tubal ectopic pregnancy at Grady Memorial Hospital. Am J Obstet Gynecol. 2003;188:1192
  7. Sowter MC, Farquhar CM, Petrie KJ, Gudex G. A randomized trial comparing single dose systemic methotrexate and laparoscopic surgery for the treatment of unruptured tubal pregnancy. Br J Obstet Gynecol. 2001;108:192
  8. Rodriguez L, Takacs P, Kang J. Methotrexate is safe for the management of interstitial ectopic pregnancy. Obstet Gynecol. 2003;101:S54
  9. Idama TO, Tuck CS, Ivory C, Ellerington MC, Travis S. Survival of cornual (interstitial) pregnancy. Eur J Obstet Gynecol Reprod Biol. 1999;84:103–105
  10. Lau S, Tulandi T. Conservative medical and surgical management of interstitial ectopic pregnancy. Fertil Steril. 1999;72:207–215
  11. Neary BA, Rose PG. Complete response of a persistent ectopic pregnancy to Dactinomycin after methotrexate failure, a case report. J Reprod Med. 1995;40:160–162

 S.F. has nothing to disclose. Y.Y. has nothing to disclose. S.K. has nothing to disclose. H.K. has nothing to disclose. Y.T. has nothing to disclose. M.O. has nothing to disclose.

 This work was presented at the meeting of the Japan Society of Obstetrics and Gynecology 2008.

PII: S0015-0282(08)04130-7

doi: 10.1016/j.fertnstert.2008.10.003

Fertility and Sterility
Volume 91, Issue 3 , Pages 929.e13-929.e15 , March 2009

Article Tools

* Image Usage & Resolution